Estradiol ( DrugBank: Estradiol )

---

7 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	5
46	悪性関節リウマチ	1
49	全身性エリテマトーデス	2
65	原発性免疫不全症候群	2
76	下垂体性ゴナドトロピン分泌亢進症	1
226	間質性膀胱炎（ハンナ型）	1
299	嚢胞性線維症	4

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04086225 (ClinicalTrials.gov)	January 17, 2019	9/9/2019	Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the Pharmacokinetics of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With Relapsing Multiple Sclerosis (RMS).	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany	NULL	Recruiting	18 Years	45 Years	Female	34	Phase 1	Germany;Poland
2	NCT03745144 (ClinicalTrials.gov)	January 17, 2019	14/11/2018	Effects of Cladribine Tablets on the PK of Microgynon®	A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in Pre-Menopausal Women With RMS	Relapsing Multiple Sclerosis (RMS)	Drug: Cladribine;Drug: Placebo;Drug: Microgynon®	Merck KGaA, Darmstadt, Germany	NULL	Completed	18 Years	45 Years	Female	24	Phase 1	Germany;Poland
3	EUCTR2014-005129-10-FI (EUCTR)	27/01/2015	12/12/2014	Multiple Sclerosis, menopause and hormone replacement therapy	Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis	Multiple sclerosis MedDRA version: 17.1;Level: LLT;Classification code 10064137;Term: Progression of multiple sclerosis;System Organ Class: 100000004852 MedDRA version: 17.1;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Femoston 2/10 Product Name: Femoston 2/10 INN or Proposed INN: ESTRADIOL HEMIHYDRATE INN or Proposed INN: DYDROGESTERONE Trade Name: Femoston 1/10 Product Name: Femoston 1/10 INN or Proposed INN: ESTRADIOL HEMIHYDRATE INN or Proposed INN: DYDROGESTERONE	Irina Elovaara	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no			Finland
4	EUCTR2006-005460-30-IT (EUCTR)	22/05/2007	27/10/2008	POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUS	POPART?MUS Prevention of Post Partum Relapses with Progestin and Estradiolin Multiple sclerosis - POPART`MUS	Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: DEMESTRIL SEPTEM INN or Proposed INN: Estradiol Trade Name: LUTENYL INN or Proposed INN: Nomegestrol	OSPEDALI CIVILI DI LIONE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: no	300		Italy
5	NCT00127075 (ClinicalTrials.gov)	June 2005	4/8/2005	POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis	POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis	Multiple Sclerosis	Drug: nomegestrol acetate;Drug: estradiol;Drug: placebo	Hospices Civils de Lyon	NULL	Active, not recruiting	18 Years	50 Years	Female	300	Phase 3	France

先頭へ

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03262740 (ClinicalTrials.gov)	September 11, 2017	24/8/2017	The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients	The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects	Rheumatoid Arthritis	Drug: BMS-986195;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)	Bristol-Myers Squibb	NULL	Completed	18 Years	40 Years	Female	58	Phase 1	United States

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03262727 (ClinicalTrials.gov)	September 1, 2017	24/8/2017	The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients	The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects	Systemic Lupus Erythematosus;Arthritic Psoriasis;Psoriasis;Inflammatory Bowel Diseases	Drug: BMS-986165;Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol)	Bristol-Myers Squibb	NULL	Completed	18 Years	40 Years	Female	49	Phase 1	United States
2	NCT00006133 (ClinicalTrials.gov)	June 2000	3/8/2000	Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus		Systemic Lupus Erythematosus	Drug: estradiol;Drug: ethinyl estradiol;Drug: medroxyprogesterone;Drug: norethindrone	National Center for Research Resources (NCRR)	University of Alabama at Birmingham	Completed	N/A	N/A	Female	970	N/A	United States

65. 原発性免疫不全症候群

---

臨床試験数 : 500 /  薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01052623 (ClinicalTrials.gov)	January 2010	19/1/2010	Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)	Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia	Ataxia Telangiectasia;Growth Failure	Drug: Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate	Johann Wolfgang Goethe University Hospitals	NULL	Recruiting	3 Years	18 Years	Both	24	Phase 4	Germany
2	EUCTR2009-015739-34-DE (EUCTR)	09/12/2009	14/09/2009	Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT)	Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT) - Growth hormone in AT (GHAT)	This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children with Ataxia telangiectasia (AT)	Trade Name: Catapresan 75, Tabletten INN or Proposed INN: Clonidinhydrochlorid Trade Name: L-Arginin-hydrochlorid-einmolar Fresenius INN or Proposed INN: Argininhydrochlorid Trade Name: Progynova 21 mite INN or Proposed INN: Estradiolvalerat Trade Name: NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung INN or Proposed INN: Somatotropin	Goethe-Universität Frankfurt/Main	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Germany

76. 下垂体性ゴナドトロピン分泌亢進症

---

臨床試験数 : 29 /  薬物数 : 44 - (DrugBank : 14) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100047299	2020-12-01	2021-06-12	The use of morning urinary gonadotropins and sexual hormones in the diagnosis and monitoring treatment of central precocious puberty	The use of morning urinary gonadotropins and sexual hormones in the diagnosis and monitoring treatment of central precocious puberty	precocious puberty	Gold Standard:gonadotropin releasing hormone stimulation test ;Index test:luteinizing hormone, follicle stimulating hormone, estradiol, prolactin, progesterone, testosterone, and human chorionic gonadotropin;	The Children's Hospital, Zhejiang University School of Medicine	NULL	Recruiting	3	10	Female	Target condition:200;Difficult condition:100		China

226. 間質性膀胱炎（ハンナ型）

---

臨床試験数 : 145 /  薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03844412 (ClinicalTrials.gov)	November 4, 2019	15/2/2019	Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments	Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments	Vestibulodynia;Temporomandibular Disorder;Fibromyalgia Syndrome;Irritable Bowel Syndrome;Migraines;Tension Headache;Endometriosis;Interstitial Cystitis;Back Pain;Chronic Fatigue Syndrome	Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream;Drug: Nortriptyline;Drug: Placebo cream;Drug: Placebo pill	Duke University	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Recruiting	18 Years	50 Years	Female	400	Phase 2	United States

299. 嚢胞性線維症

---

臨床試験数 : 1,695 /  薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05704036 (ClinicalTrials.gov)	March 2023	10/1/2023	Estrogen Patches for Adolescent and Young Adult Women With Cystic Fibrosis	Transdermal Estradiol for Adolescent and Young Adult Women With CF	Cystic Fibrosis;Hypoestrogenism	Drug: Transdermal estrogen;Drug: Placebo patch;Drug: Progesterone;Drug: Placebo pill	Johns Hopkins University	Cystic Fibrosis Foundation	Recruiting	16 Years	30 Years	Female	75	Phase 4	United States
2	NCT03724955 (ClinicalTrials.gov)	April 2019	29/10/2018	Pilot E2 for Hypogonadal Women With CFBD	Pilot Study Evaluating the Effects of Estradiol for Hypogonadal Women With Cystic Fibrosis and Osteopenia	Cystic Fibrosis Related Bone Disease	Drug: Estradiol 2 mg;Other: Placebo	Emory University	NULL	Withdrawn	18 Years	N/A	Female	0	Phase 4	United States
3	NCT02144246 (ClinicalTrials.gov)	May 2014	19/5/2014	Contraceptive Hormones and Women With Cystic Fibrosis	Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease	Cystic Fibrosis Exacerbations While on and Off Hormonal Contraception	Other: Non-hormonal period;Drug: Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg	University of Pennsylvania	Society of Family Planning	Terminated	18 Years	40 Years	Female	5	Phase 1	United States
4	NCT02036879 (ClinicalTrials.gov)	February 2014	26/12/2013	Gender Disparity and Hormones in Cystic Fibrosis	Gender Disparity and Hormones in Cystic Fibrosis	Cystic Fibrosis (CF)	Drug: Loestrin (norethindrone acetate and ethinyl estradiol)	University of Texas Southwestern Medical Center	NULL	Completed	18 Years	N/A	All	55	Early Phase 1	United States

先頭へ